CClinicalTrials.gg
Status unknownNCT05452096SHIFTPLANUpdated Jul 11, 2022

SHIFTPLAN: an RCT Investigating the Effect of a Shift Work Intervention on Fatigue, Sleep and Health.

An interventional study of Education program and ergonomic schedulling in Shift-work Disorder, Insomnia and Fatigue, sponsored by University Hospital, Antwerp. Status unknown. Per ClinicalTrials.gov, last updated 2022-07-11.

Sponsored by University Hospital, Antwerp · Not applicable, Interventional, and Supportive care

The sponsor has not verified this record recently (last verified Jun 2022), so the status shown — last known as Not yet recruiting — may be out of date.
Phase
Not applicable
Study type
Interventional
Enrollment
176
Allocation
Randomized
Sex
All
01

Study summary

Shift work is associated with disturbed life rhythms resulting from chronic exposure to circadian misalignment and sleep restriction, with long-term participation in most shift schedules causing serious health problems. Epidemiological data show that shift workers are at increased risk of sleepiness, fatigue and insomnia, cardiovascular disease, breast cancer and shift-work disorder. Prevalence estimates of shift-work disorder vary between 5% and 26,5%.

Given these widespread and serious health and functional consequences of shift work, there is a necessity for treatments that improve shift workers' health and work performance. Most non-pharmacological recommendations mention improved scheduling, bright-light exposure, napping, psychoeducation fostering sleep hygiene, and cognitive-behavioral interventions.

The effects of shift work on the health, fatigue and sleepiness of drivers have been robustly investigated in observational studies, as well as the effects of single measures such as scheduling or resting times. But studies on the effectiveness of countermeasures against the adverse impact of shift work are sparse, especially for high-risk populations such as professional drivers and controlled intervention studies are lacking. Several other investigators expounded the need for a multi-level approach to managing occupational sleep-related fatigue and workplace interventions to promote sleep and health of shift workers. Highlighting the high public-health burden associated with lack of recuperative sleep, the authors pointed out the pressing need to develop policies and implement programs aimed at improving workers' sleep health.

With SHIFTPLAN, the investigators aim to fill this gap in comprehensive approaches. To their knowledge, this is the first randomised controlled trial to systematically gauge the effect of a multimodal program that includes ergonomic shift scheduling and an educational program on well-defined health, sleep and performance outcomes in professional drivers.

Read the detailed description

The duration of the intervention will be six months. The intervention provided to the intervention group is based on evidence-based good standard of care and includes: 1) Healthy scheduling (fast forward-rotating shift schedules adapted to chronotype, adequate resting times, napping, bright-light therapy); 2) Education program for drivers (psychoeducation promoting sleep hygiene, cognitive-behavioral strategies, stress-management techniques, information on chronotherapy such as bright-light therapy and napping) The control group or "waiting-list group" will include drivers who will continue working according to the default shift schedules while being assigned to a waiting list in anticipation of the education program to which they will able to suscribe after completing the study.

02

Conditions studied

  • Shift-work Disorder
  • Insomnia
  • Fatigue
  • Mental Health Issue
  • Quality of Life
  • Coping Skills
  • Circadian Rhythm Disorders
03

In context

Chronobiology Disorders

89 studies on the registry are indexed under Chronobiology Disorders; 21 are open to participants now.

This study's planned enrollment of 176 is above the median of 65 across 58 interventional studies indexed under Chronobiology Disorders.

Browse Chronobiology Disorders studies →

Lead sponsor

University Hospital, Antwerp is the lead sponsor of 234 studies on the registry; 68 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

    • Professional drivers having worked in shifts with the transport company in full-time or ≥80% part-time employment in the company's regular backward-rotating schedule for at least two years.

Exclusion criteria

Exclusion Criteria:

  • Regular medication for high blood pressure and uncontrolled high blood pressure (defined as exceeding 140/90 mmHg) at screening, regular medication for diabetes, sleeping pills or sedative medication for depression (defined as trazodone, mirtazapine and amitriptyline). Because our secondary outcomes imply the evolution of blood-pressure and blood-sugar parameters, drivers with such pre-existing controlled or non-controlled comorbidity will not be eligible for participation.
  • High risk of moderate-to-severe obstructive sleep apnea syndrome (OSAS) as assessed with the STOP-Bang questionnaire, a simple, easy to remember and self-reportable screening tool. We will use a cut-off score of 6 or higher to indicate the presence of OSAS.
  • Drivers combining their job as a professional driver with another job elsewhere.
  • Excessive sleepiness as defined as a score in excess of 12 on the Epworth Sleepiness Scale (ESS). Although the habitual cut-off is >9, we opted for this higher threshold because we will be examining the effect of the intervention on daytime sleepiness. All applicants with an ESS >12 will be excluded and referred to a general practitioner for further evaluation.
  • A BMI higher than 35. We chose this cut-off value based on the data provided by the external occupational health service, which showed that in 2018, 42.6 % of their drivers had a mean BMI of 25-30 and 27.5 % a BMI between 30-40.
  • The presence of major depression as defined by a score exceeding the threshold of 1.75 on the Hopkins Symptom Checklist (HSCL-25), where higher scores were demonstrated to be highly indicative of depressive disorder according to the DSM-5 and characterized as "a case requiring treatment".
05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Investigator, Outcomes assessor)
Enrollment
176 participants (estimated)

Study arms

  • Active comparator
    Intervention group

    The intervention provided to the intervention group is based on evidence-based good standard of care and includes: * Healthy scheduling (fast forward-rotating shift schedules adapted to chronotype, adequate resting times, napping, bright-light therapy) * Education program for drivers (psychoeducation promoting sleep hygiene, cognitive-behavioral strategies, stress-management techniques, information on chronotherapy such as bright-light therapy and napping)

    Behavioral: Education program and ergonomic schedulling

  • No intervention
    Control group

    The control group will continue working according to the default shift schedules while being assigned to a waiting list in anticipation of the education program.

Interventions

  • BehavioralEducation program and ergonomic schedulling

    The duration: six months. The explicit choice for a multimodal intervention to be tested as a whole is in line with the assertion of other experts that workplace interventions using a single approach will not be effective. Multimodal intervention 1. Implementing healthy scheduling. This will imply fast forward-rotating shift schedules, being adapted to chronotype, allowing for adequate resting times between shifts and series of shifts, allowing for napping at work, in particular during the first two days of an early shift. 2. Education program for drivers: psychoeducation on the sleep-wake cycle chronotypes, based on the cognitive-behavioral treatment of insomnia (CBT-i), information on the impact of light on wakefulness and sleep, information on napping and creating awareness on daytime sleepiness, tools for stress reduction, physical exercise, information on healthy eating in the context of shiftwork The education program will consist of a one-day, 8-hour session.

06

What researchers measure

Primary outcomes

  1. Change in sleepiness as assessed with the Epworth Sleepiness Scale (ESS).

    The Epworth Sleepiness Scale (ESS) is a validated self-report scale that gauges daytime sleepiness. The eight items of the ESS ask the respondent how likely (s)he is to doze off or fall asleep in different situations of everyday life. Total scores can range from 0 to 24 and ESS scores exceeding 9 are considered indicative of daytime sleepiness. A drop of 2,5 units will be considered a clinical minimally important difference.

    Time frame: Assessed at baseline and monthly up to and including the final 6-month evaluation and the statistical relevance of improvement (first to last score).

Secondary outcomes

  1. Effect on fatigue indices of the drivers as assessed with the CIS (Checklist Individual Strength). It is to be noted that fatigue and sleepiness are two distinct states of being that may be present or absent independently from each other, whe

    The CIS (Checklist Individual Strength) The CIS is a validated, self-administered questionnaire assessing fatigue. It consists of 20 statements for which the respondent has to indicate on a 7-point Likert-scale to what extent the particular statement applies to him or her. The final score is obtained by adding the scores to all questions (range 20-140), where scores of 27 or higher are taken to indicate abnormal fatigue and scores ≥35 severe fatigue. Scores in excess of 76 have been associated with a high risk of chronic absenteeism in a working population. A drop of 10 units will be considered a clinical minimally important difference.

    Time frame: Evolution of CIS scores from baseline to three and six months and the statistical relevance of improvement (first to last score).

  2. Sleep outcomes as evaluated by Total sleep time (TST) and sleep efficiency (SE)

    As derived from self-recorded sleep-wake patterns by keeping a sleep-wake diary

    Time frame: Evolution at baseline, three and six months of mean total sleep time (TST) and sleep efficiency (SE)

  3. Sleep outcomes measured as scores on the Pittsburgh Sleep Quality Index (PSQI).

    The Pittsburgh Sleep Quality Index (PSQI) is a self-rated questionnaire that assesses sleep quality and disturbances. Although self-rated, the PSQI is widely used to assess sleep in sleep and shift-work research, where a global PSQI score \>5 is indicative of poor sleep.

    Time frame: scores on the PSQI at baseline, three and six months and the statistical relevance of the baseline to 6-month change

  4. General health-related quality of life (HR-QoL) as assessed with the SF-36

    The SF-36 The SF-36 is one of the most widely used generic self-report measures of health-related quality of life and consists of 36 items that are structured into nine subscales. The scales are scored from 0-100 (transformed scale = (actual raw score - lowest possible raw score)/possible raw score range) x 100), with higher scores indicating better health.

    Time frame: evolution of total SF-36 scores from baseline to three and six months and the statistical relevance of first-to-last score improvement

  5. Absenteeism: sick leave in terms of number of days off work due to illness will be derived from official records of and provided by the company

    Absenteeism: formal data collected and provided by the company.

    Time frame: Data from baseline and after six months

  6. Clinical health outcome: evolution of blood pressure as measured in mmHg

    Normal blood pressure is defined as a value lower than 140/90 mmHg

    Time frame: Evolution of blood pressure from baseline, to three and to six months and the statistical relevance of the improvement (first-to-last change).

  7. Clinical health outcome: evolution of Body Mass Index (BMI) as measured in kg/m²

    Normal BMI is defined as a value lower than 25 kg/m²

    Time frame: Evolution of BMI from baseline, to three and to six months and the statistical relevance of the improvement (first-to-last change).

  8. Clinical health outcome: evolution of fasting blood glucose as measured in mmol/l

    Normal fasting blood glucose concentration according to the WHO is a value between 3.9 and 5.6 mmol/l

    Time frame: Evolution of fasting blood glucose from baseline, to three and to six months and the statistical relevance of the improvement (first-to-last change).

  9. Clinical health outcome: evolution of glycosylated hemoglobin (HbA1c) as measured in mmol/mol

    On average, normal HbA1c for non-diabetics is \< 36 mmol/mol

    Time frame: Evolution of HbA1c from baseline, to three and to six months and the statistical relevance of the improvement (first-to-last change).

  10. Clinical health outcome: evolution of high-sensitive C-reactive protein (hsCRP) measured in mg/L

    High-sensitive C-reactive protein (hsCRP) is shown to be related to cardiovascular health. General guidelines for hsCRP scores: low risk of cardiovascular disease: less than 1.0 mg/L, average risk: 1.0 to 3.0 mg/L, high risk: above 3.0 mg/L

    Time frame: Evolution of hsCRP from baseline, to three and to six months and the statistical relevance of the improvement (first-to-last change).

  11. Mood and anxiety as gauged with the Hopkins Symptom Checklist (HSCL-25)

    This self-administrated questionnaire helps to assess and measure anxiety and depression in multiple settings. Anxiety and depression show considerable overlap in primary-care populations and its brevity and self-report format makes the scale well-suited for use in the busy primary-care setting. The scale's 25 questions are divided into two subsections relating to the presence and intensity of symptoms of depression and anxiety as experienced during the previous week. The final score ranges from 1.00 to 4.00 and is calculated by dividing the sum of the scores of all items by 25. Generally, scores over 1.75 are taken to be indicative of a major depression.

    Time frame: Assessed at baseline and at six months

Other outcomes

  1. Correlation between the intervention effects and chronotypes as determined by the Morningness-Eveningness questionnaire (MEQ): Exploratory

    This self-assessment scale is used to determine morningness-eveningness in human circadian rhythms and has 19 items subdivided into subscales. MEQ scores are to be added and can vary from 16 to 86. Scores lower or equal to 41 typify respondents as an "evening type", scores exceeding 59 as a "morning type" and scores between 42-58 as a "neutral type"

    Time frame: 6 months

07

Study locations

No study locations are listed for this record.

08

References and documents

Publications

  • Declercq I, Van Den Eede F, Roelant E, Verbraecken J. SHIFTPLAN: a randomized controlled trial investigating the effects of a multimodal shift-work intervention on drivers' fatigue, sleep, health, and performance parameters. Trials. 2022 Aug 17;23(1):662. doi: 10.1186/s13063-022-06573-6. PubMed 35978435 ↗
09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jul 11, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05452096
Lead sponsor
University Hospital, Antwerp
Collaborators
Universiteit Antwerpen
Responsible party
Sponsor
First posted
Jul 11, 2022
Start date
Oct 2022 (estimated)
Primary completion
May 2023 (estimated)
Completion
Aug 2023 (estimated)
Last update
Jul 11, 2022

Study contacts

Inge Declercq, MD
Contact
inge.declercq@uza.be
+3238213938 ext. 4331
Filip Van Den Eede, MD, PhD
study chair · Antwerp University Hospital (UZA). University of Antwerp (UA)
Johan Verbraecken, MD, PhD
study chair · Antwerp University Hospital (UZA). University of Antwerp (UA)

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Jun 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion